Recital 38, Regulation (EU) 2026/1826

In forcesince 28 Jul 2026

The application for the renewal of the approval of the active substance pyraclostrobin was submitted on 24 January 2014 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 7 March 2014 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 19 February 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 20 July and 18 September 2022. On 14 May 2019, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 17 June 2019 within the deadline given. On 19 February 2020, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 13 December 2021 within the deadline given. On 28 January 2026, the Authority adopted its updated conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance pyraclostrobin in the Standing Committee on Plants, Animals, Food and Feed on 10 March 2026. The draft renewal report and the draft implementing regulation were first discussed in the Standing Committee on 4 May 2026. The Standing Committee voted in favour of the Commission’s proposal for renewal of the approval of pyraclostrobin on 30 June 2026. As additional time is necessary for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 3 months, until 15 December 2026.